Rapid recovery of At-211 by extraction chromatography

Novel dibutyl ether resin for the purification of the Auger emitter antimony-119 from tin targets

Antimony-119 (119Sb, t1/2 = 38.19 h) is an Auger electron emitting radionuclide of interest for radiopharmaceutical therapy (RPT). The potential of 119Sb has only been explored theoretically, due to the absence of a suitable bifunctional chelator that enables the attachment of the radionuclide onto a radiopharmaceutical. Meanwhile, potential chelators are difficult to evaluate given that the production and radiochemical purification of 119Sb has not been optimized for radiopharmaceutical applications. 119Sb can be produced from proton bombardment of tin-119 (119Sn) targets on medical cyclotrons, subsequently the nanograms of radioantimony must be efficiently separated from the macroscopic (> mg) amount of target material while being recovered in a matrix suitable for chelation. To this end, a solid phase extraction (SPE) method employing a novel dibutyl ether (DBE) resin was developed to separate radioantimony from tin targets. The DBE resin was synthesized and characterized using thermogravimetric analysis, total organic carbon, and 1H nuclear magnetic resonance spectroscopy. The DBE resin exhibited excellent capacity (>8 mg Sb per gram) and integrity. Distribution coefficients (KD) for Sb(V) (KD up to 4600) and Sn(IV) (KD <0.3) showed good separation (Separation factor of >15,000) of both elements at high concentrations of HCl. Finally, dynamic separations with the DBE resin were capable of recovering up to 79 ± 2 % of radioantimony (1xxSb(III)) in 2 mL of 0.5 M sodium thioglycolate solution when separating nanogram quantities of 1xxSb from tens of milligrams of stable tin. Quantitative recovery of Sn was also achieved in just 1.5 mL of concentrated hydrochloric acid, indicating the potential for target recycling of enriched 119Sn required for pre-clinical evaluation of 119Sb.

Probing the Redox Reactivity of Alkyl Bound Astatine: A Study on the Formation and Cleavage of a Stable At-C Bond

The formation of a stable alkyl At-C bond occurs during the shipment of 211At on a 3-octanone-impregnated column and the reactivity of 211At stripped from columns has been studied. The 211At could not be recovered from the 3-octanone organic phase using nitric acid or sodium hydroxide, even up to 10 and 15.7 M, respectively. Several reducing and oxidizing agents, including hydrazine, hydroxylamine, ascorbic acid, ceric ammonium nitrate, potassium permanganate, sodium hypochlorite, and calcium hypochlorite were used to promote the recovery of 211At. The most effective reducing agent was hydroxylamine, where ∼70% of the 211At was recovered, while among oxidizing agents ceric ammonium nitrate, potassium permanganate, and sodium hypochlorite all showed near quantitative recovery of 211At. These results indicate an At-C bond is being formed during the shipment of the column and a redox reaction is required for bond cleavage to occur. DFT calculations have been used to propose several products of an AtO+-3-octanone reaction, with 4-astato-5-hydroxy-octa-3-one being the most probable.

Production, purification and formulation of nanoradiopharmaceutical with 211At: An emerging candidate for targeted alpha therapy

INTRODUCTION

Astatine-211 has attained significant interest in the recent times as a promising radioisotope for targeted alpha therapy (TAT) of cancer. In this study, we report the production of 211At via 209Bi (α, 2n) 211At reaction in a cyclotron and development of a facile radiochemical separation procedure to isolate 211At for formulation of nanoradiopharmaceuticals.

METHODS

Natural bismuth oxide target in pelletized form wrapped in Al foil was irradiated with 30 MeV α-beam in an AVF cyclotron. The irradiated target was dissolved in 2 M HNO3 followed by selective precipitation of Bi as Bi(OH)3 under alkaline condition. The radiochemically separated 211At was used for labeling cyclic RGD peptide conjugated gold nanoparticles (Au-RGD NPs) by surface adsorption. The radiochemical stability of 211At-Au-RGD NPs was evaluated in phosphate buffered saline (PBS) and human serum media.

RESULTS

The batch yield of 211At at the end of irradiation was ∼6 MBq.μA-1.h-1. After radiochemical separation, ∼80 % of 211At could be retrieved with >99.9 % radionuclidic purity. Au-RGD NPs (particle size 8.4±0.8 nm) could be labeled with 211At with >99 % radiolabeling yield. The radiolabeled nanoparticles retained their integrity in PBS and human serum media over a period of 21 h.

CONCLUSIONS

The present strategy simplifies 211At production in terms of purification and would increase affordable access to this radioisotope for TAT of cancer.

211At on gold nanoparticles for targeted radionuclide therapy application

Targeted alpha therapy (TAT) is a methodology that is being developed as a promising cancer treatment using the α-particle decay of radionuclides. This technique involves the use of heavy radioactive elements being placed near the cancer target area to cause maximum damage to the cancer cells while minimizing the damage to healthy cells. Using gold nanoparticles (AuNPs) as carriers, a more effective therapy methodology may be realized. AuNPs can be good candidates for transporting these radionuclides to the vicinity of the cancer cells since they can be labeled not just with the radionuclides, but also a host of other proteins and ligands to target these cells and serve as additional treatment options. Research has shown that astatine and iodine are capable of adsorbing onto the surface of gold, creating a covalent bond that is quite stable for use in experiments. However, there are still many challenges that lie ahead in this area, whether they be theoretical, experimental, and even in real-life applications. This review will cover some of the major developments, as well as the current state of technology, and the problems that need to be tackled as this research topic moves along to maturity. The hope is that with more workers joining the field, we can make a positive impact on society, in addition to bringing improvement and more knowledge to science.

Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future

The low range of alpha particles provides an opportunity to better target cancer cells theoretically leading to the introduction of interesting alpha emitter radiopharmaceuticals including 225Ac, 212Pb, etc. The combination of high energy and short range of alpha emitters differentiates targeted radiotherapy from other methods and reduces unwanted cytotoxicity of the cells around the tumoral tissue. Among interesting alpha emitters candidates for targeted therapy, 211At, one of the radioisotopes with the best optimal decay properties, shows great promise for targeted radiotherapy in some animal prostate cancer xenograft studies and bone micro tumors with significant effects compared to other beta and alpha emitters and also demonstrates interesting properties for clinical applications. However, production and application of this alpha emitter in the development of actinium-based radiopharmaceuticals is hampered by many obstacles. This mini-review demonstrates 211At production methods, chemical separation, radiolabeling procedures, 211At-radiopharmaceuticals and their clinical trials, transport, logistics, and costs and future trends in the field for ultimate clinical applications. This review showed that there are limited clinical trials on 211Ac-based radiopharmaceuticals, which is due to the low accessibility of this radioisotope and other limitations. However, the development programs of major industries indicate the development of 211Ac-based radiopharmaceuticals in the future.

Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply

The alpha emitter astatine-211 (211At) is a promising candidate for cancer treatment based on Targeted Alpha (α) Therapy (TAT). A small number of facilities, distributed across the United States, are capable of accelerating α-particle beams to produce 211At. However, challenges remain regarding strategic methods for shipping 211At in a form adaptable to advanced radiochemistry reactions and other uses of the radioisotope.

PURPOSE

Our method allows shipment of 211At in various quantities in a form convenient for further radiochemistry.

PROCEDURES

For this study, a 3-octanone impregnated Amberchrom CG300M resin bed in a column cartridge was used to separate 211At from the bismuth matrix on site at the production accelerator (Texas A&M) in preparation for shipping. Aliquots of 6 M HNO3 containing up to ≈2.22 GBq of 211At from the dissolved target were successfully loaded and retained on columns. Exempt packages (<370 MBq) were shipped to a destination radiochemistry facility, University of Texas MD Anderson Cancer Center, in the form of a convenient air-dried column. Type A packages have been shipped overnight to University of Alabama at Birmingham.

MAIN FINDINGS

Air-dried column hold times of various lengths did not inhibit simple and efficient recovery of 211At. Solution eluted from the column was sufficiently high in specific activity to successfully radiolabel a model compound, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1), with 211At. The method to prepare and ship 211At described in this manuscript has also been used to ship larger quantities of 211At a greater distance to University of Alabama at Birmingham.

PRINCIPAL CONCLUSIONS

The successful proof of this method paves the way for the distribution of 211At from Texas A&M University to research institutions and clinical oncology centers in Texas and elsewhere. Use of this simple method at other facilities has the potential increase the overall availability of 211At for preclinical and clinical studies.

Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy

Encouraging results from targeted α-therapy have received significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. In this review, along with 2 forthcoming reviews on chelation and clinical application of α-emitting radionuclides, The Journal of Nuclear Medicine will provide a comprehensive assessment of the field.

Production, purification and availability of 211At: Near term steps towards global access

The promising characteristics of the 7.2-h radiohalogen 211At have long been recognized; including having chemical properties suitable for labeling targeting vectors ranging from small organic molecules to proteins, and the emission of only one α-particle per decay, providing greater control over off-target effects. Unfortunately, the impact of 211At within the targeted α-particle therapy domain has been constrained by its limited availability. Paradoxically, the most commonly used production method - via the 209Bi(α,2n)211At reaction - utilizes a widely available natural material (bismuth) as the target and straightforward cyclotron irradiation methodology. On the other hand, the most significant impediment to widespread 211At availability is the need for an accelerator capable of generating ≥28 MeV α-particles with sufficient beam intensities to make clinically relevant levels of 211At. In this review, current methodologies for the production and purification of 211At - both by the direct production route noted above and via a 211Rn generator system - will be discussed. The capabilities of cyclotrons that currently produce 211At will be summarized and the characteristics of other accelerators that could be utilized for this purpose will be described. Finally, the logistics of networks, both academic and commercial, for facilitating 211At distribution to locations remote from production sites will be addressed.

Advances in 211At production at Texas A&M University

Alpha emitting radionuclides with medically relevant half-lives are interesting for treatment of tumors and other diseases because they deposit large amounts of energy close to the location of the radioisotope. Researchers at the Cyclotron Institute at Texas A&M University are developing a program to produce 211At, an alpha emitter with a medically relevant half-life. The properties of 211At make it a great candidate for targeted alpha therapy for cancer due to its short half-life (7.2 h). Astatine-211 has now been produced multiple times and reliability of this process is being improved.